Nucleome Therapeutics
Latest round
- Series A
Last raised
- Oct 2022
Total raised
- $42M
Investors
- 5
About Nucleome Therapeutics
Based in the UK, and founded in 2019, Nucleome Therapeutics Limited operates as a biotech firm. The company was founded by its CEO Danuta Jeziorska, Jim Hughes, and James Davies. Nucleome Therapeutics develops and offers various precision medicines for patients suffering from lymphocytes and autoimmune-related diseases. The company provides a therapeutics technology platform, which is a 3D genome analysis platform that uses machine learning models to predict disease-related genetic variations.
Who invested in Nucleome Therapeutics
5 investors across 1 round
See all investors in Nucleome Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Oct 19, 2022
Amount
$42M
Investors
Questions about Nucleome Therapeutics
Who invested in Nucleome Therapeutics?
Nucleome Therapeutics has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nucleome Therapeutics raised?
Nucleome Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Nucleome Therapeutics last raise money?
Nucleome Therapeutics's most recent round on record is a Series A, in Oct 2022.
What does Nucleome Therapeutics do?
Based in the UK, and founded in 2019, Nucleome Therapeutics Limited operates as a biotech firm.
Where is Nucleome Therapeutics headquartered?
Nucleome Therapeutics is headquartered in Oxford, UK.
Which VCs invest in companies like Nucleome Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Nucleome Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Nucleome Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.